Articles tagged with Prostate Cancer
The growing US population and increased life expectancy necessitate new approaches to prostate cancer treatment. Researchers are exploring targeted therapies, immunotherapy, and precision radiation targeting to improve treatment outcomes for older patients.
Researchers found that high levels of COUP-TFII can overcome a natural barrier to prostate cancer progression, allowing tumor cells to grow and spread throughout the body. The study suggests that COUP-TFII is an important 'second hit' for the progression of prostate cancer and metastasis.
A study of almost 1,000 men diagnosed with prostate cancer found that active surveillance can reduce or avoid side effects such as incontinence and impotence. Many low-risk tumours are slow-growing and may never develop symptoms during a lifetime.
Researchers at Baylor College of Medicine discovered a positive feedback loop between Notch and TGF beta proteins that maintains basal cell population in the prostate. Disrupting this loop may contribute to prostate cancer initiation.
A study by Loyola Medicine found that only 4.8% of web sites describing prostate cancer were written below a high school reading level, highlighting the need for easier-to-read patient education materials.
Researchers have identified a new molecular marker, β2-syntrophin, which can help differentiate between low-risk and high-risk types of prostate cancer. This breakthrough discovery could lead to more accurate diagnoses and personalized treatment plans, ultimately improving patient outcomes.
Men treated with proton therapy for prostate cancer reported excellent urinary and bowel function, similar to healthy controls. However, sexual function was affected by hormone therapy and other factors, with significant differences noted between groups.
Researchers developed a noninvasive assay to monitor treatment response in patients with metastatic prostate cancer. The assay measures androgen receptor signaling pathway activity in circulating tumor cells, allowing for early detection of resistance to treatment.
A new study found that men with high blood pressure, high blood sugar, and a high body mass index are more likely to die from prostate cancer. Researchers also discovered that combining these metabolic factors increases the risk of death, suggesting that lifestyle changes may help prevent this.
A long-term study found that radiotherapy after surgery significantly improves biochemical progression-free survival and local control for high-risk prostate cancer patients. However, its effects on clinical progression-free survival and overall survival are less clear.
Researchers at Queen Mary University of London discovered that the characteristic shape of a man's urine stream can be used to diagnose urinary problems, including those associated with prostate enlargement. The study found a strong correlation between the shape of the urine flow pattern and the maximum urine flow rate.
Researchers found that high levels of activated Stat5 protein in prostate cancer after surgery are associated with increased risk of recurrence and death. The study suggests Stat5 could serve as a biomarker to help guide patients and physicians for future treatment.
Researchers at the University of Missouri have developed a new gold nanoparticle treatment for prostate cancer that uses radioactive gold nanoparticles. The treatment has shown to be safe and effective in dogs, which are the only other mammal to naturally contract aggressive prostate cancer, making it a promising lead for human trials.
Research by Centre INRS–Institut Armand-Frappier and Centre de recherche du Centre hospitalier de l'Université de Montréal found a possible association between night work and increased risk of prostate, colon, lung, bladder, rectal, and pancreatic cancer. Exposure to light at night can disrupt the body's natural sleep-wake cycle.
A new study reveals that curcumin, a compound found in turmeric, can inhibit the formation of metastases in prostate cancer. Curcumin reduces inflammation and decreases the expression of proteins that promote metastasis, resulting in a decline in tumor cell growth.
A six-gene signature has been identified that can predict survival in men with aggressive prostate cancer. The test uses blood samples and shows promise for determining the course of action for patients, clinical trial eligibility, and targeted studies.
Researchers discovered a new function of PARP-1 that regulates both DNA damage repair and androgen receptor activity, suggesting that inhibiting this enzyme could slow prostate cancer growth. This finding provides a new approach to treating advanced prostate cancer, which currently has limited treatment options.
Researchers identified genetic signatures that can predict the progression of castration-resistant prostate cancer, with patients having the signature living an average of 9.2 months compared to 21.6 months without the signature. These findings hold promise for improving patient outcomes and enabling better clinical trials.
Researchers have designed a blood test that can detect aggressive prostate cancers by analyzing the pattern of gene activity in blood cells. The test, which reads genetic changes like a barcode, can accurately identify patients with advanced prostate cancers and predict their survival time.
Researchers create precision blood test that uses gene patterns in blood cells to identify advanced-stage prostate cancer patients with worst prognosis. The test can be used to select those in need of immediate treatment.
Researchers found that common polymorphisms in the T2R38 gene were correlated with the incidence of bacterial sinus infections, demonstrating a genetic link to individual differences in respiratory infection susceptibility. In companion pieces, studies on PSD-95 expression and progranulin deficiency shed light on potential therapeutic ...
Emanuel Hamelburg, a Boston-area prostate cancer survivor, has been recognized for his dedication to cancer awareness and advocacy. He was awarded the Survivor Circle Award by the American Society for Radiation Oncology (ASTRO) in 2012.
Prostate cancer cases expected to reach nearly 242,000 diagnoses in 2012. New guidelines introduce active surveillance as a viable alternative to immediate treatment for low-risk tumors.
Researchers at Thomas Jefferson University found that contrast-enhanced ultrasound detected higher-grade prostate cancers in 55% of patients, compared to 17% with conventional biopsy methods. The technique uses microbubbles to measure changes in blood flow and requires fewer needle biopsies.
A study has identified 12 genetic markers associated with erectile dysfunction in prostate cancer patients treated with radiation. The findings may help clinicians predict complications and develop therapies to alleviate side effects.
Research finds that obesity promotes prostate cancer growth by changing gene expression in fat surrounding the prostate, increasing risk of aggressive disease. The study suggests a personalized approach to lifestyle and therapeutic strategies for overweight men with prostate cancer.
A recent study by Mayo Clinic researchers found that men with high levels of 'cancer-specific anxiety' after prostate cancer surgery are more likely to experience low sexual satisfaction and depression. Counseling may be beneficial in addressing these concerns and improving quality of life for these patients.
A new research model estimates that men with low-risk prostate cancer who choose active surveillance may live 6.4 years without treatment, while those who undergo immediate radical prostatectomy may gain an average of 1.8 months of additional life.
A new study in The Journal of Urology presents promising results on the use of MRI to assess eligibility for active surveillance in men with clinically low risk prostate cancer. The findings suggest that clear tumor visualization on MRI is predictive of disease status upgrades on confirmatory biopsy, highlighting the potential of MRI t...
A recent study has confirmed that an association between XMRV and prostate cancer was due to laboratory contamination. The researchers found that the virus was introduced into prostate tissue samples through contact with a different cell line, which had been contaminated with XMRV in the 1990s.
A phase 3 trial confirms abiraterone acetate's efficacy in extending average survival time to 15.8 months for castration-resistant prostate cancer patients. The treatment, which blocks testosterone production, also has a good safety profile.
Hartzband and Groopman argue that expert recommendations often ignore vital dimensions of life and are based on flawed calculations. They propose a new approach for individual patients to weigh risk and benefit, and emphasize the importance of nuanced judgment in medical decisions.
Researchers found that fusion-negative prostate cancers have different DNA methylation patterns than healthy cells, with increased EZH2 enzyme activity. This discovery may lead to more specific treatments and improved diagnosis for prostate cancer patients.
Researchers will investigate how sulforaphane in broccoli affects prostate tissue gene expression and metabolism in men at risk of developing prostate cancer. The study aims to provide evidence that diets rich in cruciferous vegetables or sulforaphane can reduce the likelihood of metastatic cancer.
A study published in Archives of Neurology found an association between Parkinson disease and an increased risk of prostate cancer and melanoma in patients with PD and their relatives. The research used a Utah genealogic database and a statewide cancer registry to examine the relationship between the two diseases.
A study published in Cancer Epidemiology, Biomarkers & Prevention establishes the association of IL-16 with prostate cancer in men of both African and European descent. Researchers found new polymorphisms in the gene unique to African Americans that confer risk, providing a potential biomarker for prostate cancer.
Researchers at Washington State University have identified a biological mechanism connecting trichomoniasis, a curable sexually transmitted disease, to an increased risk of developing prostate cancer in men. The study reveals that the parasite activates a series of proteins, with one protein acting as a key regulator in this process.
A multicenter study found that taking aspirin is associated with a lower risk of death from prostate cancer, especially in high-risk disease. The study analyzed data from almost 6,000 men with prostate cancer treated with surgery or radiotherapy, and the results showed a significant reduction in mortality rates and cancer recurrence.
Researchers found that tamoxifen effectively suppresses gynecomastia and breast pain in men with prostate cancer. Treatment with tamoxifen was more successful than with aromatase inhibitors or radiotherapy in reducing breast symptoms.
A new study published in The Journal of Urology reports that PSA testing has led to improved survival rates for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body. The disparity between African American and Caucasian men has been resolved, with African American men now having a compara...
A study led by Vanderbilt-Ingram Cancer Center finds that black men with prostate cancer receive lower quality surgical care than white men. Black men are less likely to use high-volume surgeons and hospitals, resulting in longer hospital stays and higher mortality rates.
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
A recent study published in Carcinogenesis found that cooking red meats at high temperatures, especially pan-frying, increases the risk of advanced prostate cancer. Men who consumed more than two servings of red meat cooked at high temperatures were 40% more likely to develop advanced prostate cancer.
Researchers developed a new prostate cancer screening method that combines drug therapy with changes in PSA levels to identify men with high-risk prostate cancer. The study showed that using PSA with these drugs can help differentiate between prostate cancer and benign disease, even in patients with difficult diagnoses.
Researchers reviewed clinical trials on calcium and vitamin D supplements for men with prostate cancer undergoing hormone therapy, finding that these supplements did not prevent bone loss. The study suggests that these supplements may actually increase the risk of cardiovascular disease and aggressive prostate cancer.
Researchers found two opposing proteins regulating the same set of genes in prostate cancer, suggesting potential therapeutic targets. The study identified genetic markers associated with tumor relapse, which could help predict patient outcomes.
A new study found that over half of malignant prostate cancers have both high-risk HPV 18 and EBV, with HPV alone present in 70% of the cancers. The research suggests a potential collaboration between the two viruses to promote cancer cell survival.
The study suggests that eliminating the PSA test would result in more men being diagnosed with metastatic prostate cancer, leading to higher mortality rates. Prostate cancer death rates have been reduced by nearly 40% over the past 20 years, largely due to early detection through PSA testing.
The study found that without PSA testing, approximately 25,000 cases of advanced prostate cancer would occur in 2008, three times the actual number observed. This would result in more men experiencing aggressive disease with limited treatment options.
A new study from Harvard School of Public Health found that men with prostate cancer are more likely to die from preventable conditions such as heart disease than the disease itself. The study emphasizes the importance of healthy lifestyle changes in prostate cancer management.
Researchers found that paxillin regulates cell growth even in hormone therapy-resistant tumors, providing a new treatment target for advanced prostate cancer. The discovery could potentially lead to the development of targeted therapies that selectively attack cancer cells while leaving healthy cells intact.
Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. The study provides new insight into the mechanism of miR-125b regulation of castrate-resistance prostate cancer.
Researchers have found a new treatment for prostate cancer using gold nanoparticles produced from chemicals in tea leaves, reducing tumors by 80 percent and requiring doses thousands of times smaller than chemotherapy. The nanoparticles are attracted to tumor cells and destroy them efficiently.
A study published in Journal of Biological Chemistry found that prostate cancer cells lacking the protein SPDEF are unable to establish colonies at possible sites of metastasis, highlighting a potential biomarker for untreated cancers. Researchers hope to regulate SPDEF expression to prevent cancer cell metastasis.
Researchers at the University of Houston will pursue projects related to prostate cancer, diabetes, and obesity with funding from the NIH and DOD. The center's eight active NIH grants account for more than $18 million in research funding.
Researchers have discovered a novel mechanism for generating cancer-driving genes, bypassing chromosomal translocation. The SLC45A3-ELK4 fusion RNA promotes prostate cancer cell growth and disease progression in human samples.
Researchers found African-American survivors have unmet needs in dealing with fears of recurrence, while spouses report concerns about stress and anxiety. The study highlights the importance of culturally appropriate interventions, including improved communication and symptom management for better outcomes.
A new line of radioisotope therapy, Radium-223 chloride, has been shown to extend the lives of prostate cancer patients with advanced tumors that have spread to bone. The treatment has a short range of penetration and is usually well-tolerated, with serious side effects being rare.
A team of UC Davis investigators found that a p53 genetic mutation may initiate prostate cancer, differing from the current conventional wisdom. The study developed a mouse model with the mutation, which significantly increased the likelihood of developing prostate cancer.
A new medication, abiraterone acetate, has been shown to slow the spread of metastatic prostate cancer while maintaining quality of life in patients. The study involved 1,088 men and demonstrated improved survival and reduced need for chemotherapy and pain medications.